Von Willebrand Factor Levels in Patients With Liver Cirrhosis and Portal Hypertension

Launched by ASSIUT UNIVERSITY · Nov 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the role of Von Willebrand Factor (VWF) levels in patients who have liver cirrhosis and portal hypertension, which are serious conditions affecting the liver and blood flow. The researchers want to understand how VWF levels might change in these patients and what that could mean for their health.

To be eligible for this study, participants must be adults over 18 years old, regardless of gender, and have any stage of liver cirrhosis, whether it’s compensated (where the liver can still function relatively well) or decompensated (where the liver is failing). However, people with certain conditions, such as acute liver disease, infections, or those who have had a liver transplant, won't be able to join this trial. If you participate, you can expect to undergo testing to measure your VWF levels, and your health will be monitored throughout the study. This trial is currently not recruiting participants, but it aims to provide valuable insights for improving care for patients with liver conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • adult patient \>18 years
• • both sex male and female
• • all stages of liver cirrhosis (compensated and decompensated)
• Exclusion Criteria:
• • acute liver disease
• • any hereditary or acquired diseases that affect VWF level.
• • sepsis and infections (including spontaneous bacterial peritonitis), patients with any infectious symptoms at the time of study (increasing VWF Ag levels).
• • active extrahepatic malignancies.
• • previous liver transplantation.
• • any medication affect VWF level.